Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 116

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1A
Chunk 116
---
 in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information; 

•the commencement, enrollment or results of any future clinical trials we may conduct, or changes in the development status of our product candidates; 

•adverse results from delays in or termination of clinical trials; 

•unanticipated serious safety concerns related to the use of our product candidates; 

•lower than expected market acceptance of our product candidates following approval for commercialization; 

•changes in financial estimates by us or by any securities analysts who might cover our stock; 

•conditions or trends in our industry, including changes in the structure of healthcare payment systems; 

•changes in the market valuations of similar companies; 

•stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the pharmaceutical industry; 

•publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; 

•announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; 

•announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; 

•investors’ general perception of our company and our business; 

•recruitment or departure of key personnel; 

•overall performance of the equity markets; 

•trading volume of our common stock; 

•disputes or other developments relating to intellectual property rights, including patents, litigation matters and our ability to obtain, maintain, defend, protect and enforce patent and other intellectual property rights for our technologies; 

•significant lawsuits, including patent or stockholder litigation; 

•proposed changes to healthcare laws in the United States or foreign jurisdictions, or speculation regarding such changes; 

•general economic, political and market conditions and overall fluctuations in the financial markets in the United States and abroad, including as a result of pandemics and geopolitical events; 

•other events or factors, including those resulting from war, incidents of terrorism, or responses to these events; and

•other events or factors, many of which are beyond our control. 

In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and